On Monday, Syndax Pharmaceuticals Inc (NASDAQ: SNDX) opened lower -1.96% from the last session, before settling in for the closing price of $12.77. Price fluctuations for SNDX have ranged from $12.52 to $25.34 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 1801.91%. Company’s average yearly earnings per share was noted -22.00% at the time writing. With a float of $81.08 million, this company’s outstanding shares have now reached $85.57 million.
Let’s determine the extent of company efficiency that accounts for 184 employees. In terms of profitability, gross margin is -169.78%, operating margin of -1942.5%, and the pretax margin is -1796.46%.
Syndax Pharmaceuticals Inc (SNDX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Syndax Pharmaceuticals Inc is 5.02%, while institutional ownership is 100.30%. The most recent insider transaction that took place on Jun 14 ’24, was worth 25,037. In this transaction Chief Financial Officer of this company bought 1,250 shares at a rate of $20.03, taking the stock ownership to the 52,623 shares.
Syndax Pharmaceuticals Inc (SNDX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -22.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.50% during the next five years compared to -0.41% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Check out the current performance indicators for Syndax Pharmaceuticals Inc (SNDX). In the past quarter, the stock posted a quick ratio of 6.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 66.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.63, a number that is poised to hit -1.00 in the next quarter and is forecasted to reach -3.76 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
Looking closely at Syndax Pharmaceuticals Inc (NASDAQ: SNDX), its last 5-days average volume was 3.09 million, which is a jump from its year-to-date volume of 1.29 million. As of the previous 9 days, the stock’s Stochastic %D was 12.10%. Additionally, its Average True Range was 0.73.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 1.19%, which indicates a significant decrease from 3.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.55% in the past 14 days, which was lower than the 61.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.67, while its 200-day Moving Average is $19.75. However, in the short run, Syndax Pharmaceuticals Inc’s stock first resistance to watch stands at $12.71. Second resistance stands at $12.91. The third major resistance level sits at $13.06. If the price goes on to break the first support level at $12.36, it is likely to go to the next support level at $12.21. Now, if the price goes above the second support level, the third support stands at $12.01.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats
There are currently 85,358K shares outstanding in the company with a market cap of 1.07 billion. Presently, the company’s annual sales total 0 K according to its annual income of -209,360 K. Last quarter, the company’s sales amounted to 12,500 K and its income totaled -84,130 K.
